

Involvement of both β_2 - and β_3 -adrenoceptors in the inhibition of neurogenic contractions of mouse isolated urinary bladder

Céline Rouget, Timothy Westfall, Moèz Rekik, Philippe Lluel, Stefano Palea

N° Tue 205

UROsphere, Faculty of Pharmaceutical Sciences, 35 Chemin des Maraîchers, Toulouse, France

Objectives

While it is well established that stimulation of β -adrenoceptors (β -ARs) produces urinary bladder smooth muscle relaxation, very little is known about how β -AR stimulation affects neuronally mediated bladder contractions. Relaxation of basal tension and pre-contracted urinary bladder strips has been shown to be mediated by both β_2 - and β_3 -ARs in rat (1) and pig (2) and by β_3 -AR in dog (1), primates (3) and human (4, 5). Recently, the inhibition of EFS-induced contractions of human urinary bladder by stimulation of β_3 -ARs has been demonstrated (6).

The purpose of the present study was to characterize the β -AR subtypes involved in the inhibition of neurogenic contractions of mouse urinary bladder.

Methods



- Urinary bladders were obtained from adult female C57/Bl6 mice (aged 11-13 weeks) sacrificed by cervical dislocation.
- Bladders were bisected and bladder halves mounted into 5 mL organ baths under 0.5 g of initial tension in the presence of prazosin (1 μ M) in order to block α_1 -ARs.
- ICI118,551 (β_2 -AR antagonist at 30 nM), L748,337 (β_3 -AR antagonist at 3 or 10 μ M) or vehicle (0.001% DMSO in distilled water) were added to the organ bath.
- 15 min later, tissues were subjected to EFS using the following parameters: maximal current, frequency of 2.5 Hz, pulse duration 0.3 ms, trains of pulses 2 s every minute.
- Once responses to EFS stabilized, cumulative concentration-response curves to β -AR agonists (fenoterol, a β_2 -AR selective agonist; CL316,243, a β_3 -AR selective agonist; isoproterenol, a non-selective β -AR agonist) were constructed.
- Results are expressed as percent inhibition of EFS-induced contractions.

Conclusions

The current results demonstrate that stimulation of both β_2 - and β_3 -ARs produces inhibition of neuronally-mediated contractions of mouse urinary bladder. CL316,243 acts exclusively through stimulation of β_3 -ARs, whereas fenoterol and isoproterenol appear to activate mainly β_2 -ARs. In addition, the stimulation of β_2 -ARs produces a greater degree of inhibition than stimulation of β_3 -ARs, suggesting a predominant role of β_2 -ARs. Further studies are required to define whether the effects of β -AR stimulation on EFS-induced contractions are solely due to a post-junctional action or whether pre-junctional receptors are also involved.



Results

Effects of the selective β_3 -AR agonist CL316,243 on EFS-induced contractions of mouse urinary bladder strips



- L748,337 (but not ICI118,551) significantly inhibited the effects of CL316,243 without affecting the maximal response with a pA₂ value of 7.00, that is similar to the affinity value (pK_i = 6.5) reported at rat recombinant β_3 -ARs (7).


Effects of β -AR antagonists on fenoterol and isoproterenol-mediated inhibition of EFS-induced mouse urinary bladder strip contractions



- In contrast, L748,337 inhibited the fenoterol and isoproterenol effects only at relatively high concentrations (pA₂ = 5.79 and 5.49, respectively).

Comparison of inhibitory effects of β -AR agonists on EFS-induced mouse urinary bladder strip contractions

- Both fenoterol and isoproterenol were able to inhibit EFS-induced contractions of mouse urinary bladder strips with similar potency and maximal inhibition of approximately 65%.
- CL316,243 had similar potency, but only produced a maximal inhibition of 36%.



References

- Yamazaki *et al*, Br J Pharmacol, 124:593-599, 1998.
- Yamanishi *et al*, Br J Pharmacol, 135:129-134, 2002.
- Takeda *et al*, Jpn J Pharmacol, 88:108-113, 2002.
- Igawa *et al*, Br J Pharmacol, 126:819-825, 1999.
- Fujimura *et al*, J Urol, 161:680-685, 1999.
- Rekik *et al*, Poster n° Tue 204, poster session FC08 of this meeting.
- Candelore *et al*, J Pharmacol Exp Ther, 290:649-655, 1999.
- Kobayashi *et al*, J Pharmacol Exp Ther, 297:666-671, 2001.